At study entry, acromegaly was clinical and biochemical active in all included patients, requiring second-line therapies median GH: 4.5 ng/mL IQR: 4.2, IGF-I: 371 ng/mL IQR: 372, IGF-I x ULN: 1.75 IQR:1.5. This evidence concerns the gene GH1 and acromegaly.